Onxeo S.A (CPH:ONXEO) (Paris:ONXEO), a clinical-stage biotechnology company, announced on Monday the receipt of a communication from the European Patent Office (EPO) informing the company of its intent to grant a new patent strengthening the European protection of compounds sourced from Onxeo's platON platform.
The company said this new patent strengthens the patent portfolio around AsiDNA, Onxeo's first-in-class DNA Damage Response (DDR) inhibitor. It protects AsiDNA and related compounds, as such and for their therapeutic use, in particular for the treatment of cancers, alone or in combination with other agents such as radiotherapy, chemotherapy or other tumour DNA-damaging agents.
This patent will provide a term of protection valid until mid-2031, which could be further extended until 2036 via the supplementary protection certificate (SPC) system. It completes the already robust set of 9 patent families securing the protection of AsiDNA and its related compounds, Onxeo added.
Onxeo specialises in the development of drugs targeting tumour DNA Damage Response (DDR) in oncology, in particular against rare or resistant cancers.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886